Study of Alwextin® Cream in Treating Epidermolysis Bullosa

Status Completed

Clinical Trial Summary

The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.

Clinical Trial Description

Potential subjects came to the for a screening visit. Eligible subjects had baseline assessments performed and were provided study medication, allantoin 3% cream. Subjects were instructed to apply the study medication to the entire body once daily and to keep daily record of study medication use. Subjects returned every 4 weeks for a total of 12 weeks for repeat assessments. ;

Study Design

Related Conditions & MeSH terms

Epidermolysis Bullosa

Clinical Trial Details

NCT number	NCT00825565
Study type	Interventional
Source	Northwestern University
Contact
Status	Completed
Phase	Phase 2
Start date	February 2009
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00380640` - The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa	Phase 2
Completed	`NCT00004761` - Establishment of the National Epidermolysis Bullosa Registry	N/A
Completed	`NCT01263379` - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa	Phase 1/Phase 2
Completed	`NCT01716169` - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care	N/A
Withdrawn	`NCT01454687` - Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes	N/A
Completed	`NCT00014729` - Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa	Phase 1
Recruiting	`NCT05838092` - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)	Phase 3
Recruiting	`NCT03269474` - Computational Drug Repurposing for All EBS Cases
Completed	`NCT03068780` - Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa	Phase 3
Terminated	`NCT02090283` - Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT02582775` - MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs	Phase 2
Recruiting	`NCT04213703` - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Completed	`NCT02384460` - ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 3
Terminated	`NCT02670330` - Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa	Phase 3
Terminated	`NCT01619670` - A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa	Phase 4
Recruiting	`NCT01340235` - Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin	Phase 3
Completed	`NCT02014376` - Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT04217538` - Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
Completed	`NCT03942250` - Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients	N/A
Completed	`NCT01033552` - Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs	Phase 1/Phase 2